Abstracts tagged "Antinuclear antibodies (ANA) and autoantibodies"

Abstract Number: 796 • 2016 ACR/ARHP Annual Meeting
Establishment of an International Autoantibody Standard for Anti-DFS70/LEDGF Antibodies: Proof-of-Concept Study for a Novel Strategy for the Setting up of International Autoantibody Standards
Alessandra Dellavance¹, Danielle Baldo¹ and Luis Eduardo C. Andrade², ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil
Background/Purpose: Robust, certified, and traceable reference material for autoantibody testing is vital for the validity of results obtained in the clinical laboratory. International standards for…
Abstract Number: 2854 • 2016 ACR/ARHP Annual Meeting
Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern
Andressa Mathias¹, Alessandra Dellavance², José Sá³, Felipe Muramoto⁴, Valdecir Marvulle⁵ and Luis Eduardo C. Andrade⁶, ¹Immunology Division, Fleury Medicine and Health Laboratories, SAO PAULO, Brazil, ²Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ³Infomation Technology Department, Fleury Medicine and Health Laboratories, SAO PAULO, Brazil, ⁴Information Technology Departmente, Fleury Medicine and Health Laboratories, SAO PAULO, Brazil, ⁵Statistics Department, Universidade Federal de São Paulo, SAO PAULO, Brazil, ⁶Rheumatology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: The nuclear dense fine speckled (DFS) pattern observed in the ANA assay on HEp-2 cells is strongly associated with autoantibodies to the 70/75kD lens…
Abstract Number: 27 • 2013 ACR/ARHP Annual Meeting
Specificity Of Autoantibodies In Patients With Rheumatologic Inflammatory Syndrome Following Mineral Oil Injections Is Similar To Those In Mice With Adjuvant Mineral Oil-Induced Autoimmunity
Minoru Satoh¹, Olga Vera-Lastra², Claudia Martínez³, Jesús Sepulveda- Delgado³, Luis J. Jara⁴, Raúl Vargas-Ramírez⁵, Beatriz Teresita Martin-Marquez⁶, S. John Calise⁷, Edward K.L. Chan⁷ and Monica Vázquez-Del Mercado⁸, ¹Medicine, University of Florida, Gainesville, FL, ²Internal Medicine, MD, Mexico City, Mexico, ³Hospital de Especialidades Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico, ⁴Research and Education, Hospital de Especialidades Centro Medico La Raza, México City, Mexico, ⁵Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, ⁶Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Guadalajara, Mexico, ⁷Oral Biology, University of Florida, Gainesville, FL, ⁸Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Hospital Civil JIM, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico
Background/Purpose: Intraperitoneal injection of pristane or adjuvant mineral oil (incomplete Freund's adjuvant) in non-autoimmune strains of mice mainly induces autoantibodies to U1RNP and Su/argonaute2 (Ago2). …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].